6.5亿美元!礼来押注AI平台,开发“增肌”新药

药时代
Jun 12, 2025

2025年6月11日,礼来与Juvena Therapeutics达成了一项超6.5亿美元的合作协议,双方将共同开发和商业化多款增肌药物。又是增肌。早在2023年,礼来就以高达19.2亿美元收购了Versanis Bio,获得了一款减脂增肌候选药物ActRII单抗Bimagrumab。据悉,该药物是靶向ActRII在研药物中临床进展最快的。对比两笔交易,Juvena的亮点在于旗下AI驱动平台...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10